hesim: Health Economic Simulation Modeling and Decision Analysis

Health economic models simulate the costs and effects of health technologies for use in health technology assessment (HTA) to inform efficient use of scarce resources. Models have historically been developed using spreadsheet software (e.g., Microsoft Excel) and while use of R is growing, general purpose modeling software is still limited. hesim helps fill this gap by facilitating parameterization, simulation, and analysis of economic models in an integrated manner. Supported model types include cohort discrete time state transition models (cDTSTMs), individual continuous time state transition models (iCTSTMs), and partitioned survival models (PSMs), encompassing Markov (time-homogeneous and timeinhomogeneous) and semi-Markov processes. A modular design based on R6 and S3 classes allows users to combine separate submodels for disease progression, costs, and utility in a flexible way. Probabilistic sensitivity analysis (PSA) is used to propagate uncertainty in model parameters to model outputs. Simulation code is written in C++ so complex simulations such as those combining PSA and individual simulation can be run much more quickly than previously possible. Decision analysis within a cost-effectiveness framework is performed using simulated costs and quality-adjusted life years (QALYs) from a PSA.

[1]  G. Torrance Measurement of health state utilities for economic appraisal. , 1986, Journal of health economics.

[2]  David R. Cox,et al.  The Theory of Stochastic Processes , 1967, The Mathematical Gazette.

[3]  Malcolm J Price,et al.  Parameterization of treatment effects for meta‐analysis in multi‐state Markov models , 2011, Statistics in medicine.

[4]  Hein Putter,et al.  mstate: An R Package for the Analysis of Competing Risks and Multi-State Models , 2011 .

[5]  Gianluca Baio,et al.  R You Still Using Excel? The Advantages of Modern Software Tools for Health Technology Assessment. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  Doug Coyle,et al.  A technique for approximating transition rates from published survival analyses , 2019, Cost Effectiveness and Resource Allocation.

[7]  Gianluca Baio,et al.  Bayesian Methods in Health Economics , 2012 .

[8]  J. de Haes,et al.  Quality-adjusted survival analysis. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Nicky J Welton,et al.  Network Meta-Analysis for Decision-Making , 2018 .

[10]  N. Devlin,et al.  The Influence of Cost-Effectiveness and Other Factors on NICE Decisions , 2010, Health economics.

[11]  S. Chick,et al.  A taxonomy of model structures for economic evaluation of health technologies. , 2006, Health economics.

[12]  Allan Wailoo,et al.  The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis , 2013, Rheumatology.

[13]  Matt Stevenson,et al.  Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA. , 2007, Health economics.

[14]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[15]  Gianluca Baio,et al.  Bayesian Cost-Effectiveness Analysis with the R package BCEA , 2017 .

[16]  S. Griffin,et al.  Distributional cost-effectiveness analysis: a tutorial , 2016 .

[17]  Devin Incerti,et al.  Multi-state network meta-analysis of cause-specific survival data , 2020, medRxiv.

[18]  H Putter,et al.  Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.

[19]  Simon G Thompson,et al.  Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost-effectiveness evaluations. , 2005, Health economics.

[20]  Claire Williams,et al.  Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[21]  Marta Soares,et al.  Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where Are We Now? , 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[22]  Ren Johansen An Empirical Transition Matrix for Non-homogeneous Markov Chains Based on Censored Observations , 1978 .

[23]  Gianluca Baio,et al.  survHE: Survival Analysis for Health Economic Evaluation and Cost-Effectiveness Modeling , 2020, J. Stat. Softw..

[24]  Anthony O'Hagan,et al.  Modelling SF-6D health state preference data using a nonparametric Bayesian method. , 2007, Journal of health economics.

[25]  O. Norheim,et al.  Using Cost-Effectiveness Analysis to Address Health Equity Concerns , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  Hein Putter,et al.  Reduced-rank proportional hazards regression and simulation-based prediction for multi-state models. , 2008, Statistics in medicine.

[27]  Fernando Alarid-Escudero,et al.  An Overview of R in Health Decision Sciences , 2017, Medical decision making : an international journal of the Society for Medical Decision Making.

[28]  Christopher H Jackson,et al.  flexsurv: A Platform for Parametric Survival Modeling in R. , 2016, Journal of statistical software.

[29]  Gianluca Baio,et al.  When Simple Becomes Complicated: Why Excel Should Lose its Place at the Top Table , 2019, Global and Regional Health Technology Assessment.

[30]  Isabelle Durand-Zaleski,et al.  Markov Models for Health Economic Evaluations: The R Package heemod , 2017, 1702.03252.

[31]  Gianluca Baio,et al.  Efficient Monte Carlo Estimation of the Expected Value of Sample Information Using Moment Matching , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[32]  Andrew Briggs,et al.  An Introduction to Markov Modelling for Economic Evaluation , 1998, PharmacoEconomics.

[33]  Nicky J Welton,et al.  Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves , 2012, BMC Medical Research Methodology.

[34]  P Glasziou,et al.  Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  M. Sculpher,et al.  Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. , 2005, Health economics.

[36]  Jeremy E. Oakley,et al.  Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[37]  Eleftherios Sideris,et al.  NICE DSU TECHNICAL SUPPORT DOCUMENT 19 : PARTITIONED SURVIVAL ANALYSIS FOR DECISION MODELLING IN HEALTH CARE : A CRITICAL REVIEW REPORT BY THE DECISION SUPPORT UNIT 2 June 2017 , 2017 .

[38]  Pedro M. Valero-Mora,et al.  ggplot2: Elegant Graphics for Data Analysis , 2010 .

[39]  K. Phillips,et al.  Health technology assessment and private payers' coverage of personalized medicine. , 2011, Journal of oncology practice.